Monkeypox Virus Is Inhibited by Nucleoside Analogues Including the Acyclic Phosphonates Adefovir and Tenofovir In Vitro

Mpox, caused by the orthopoxvirus monkeypox virus (MPXV), has garnered worldwide attention during a global outbreak in 2022 and in an ongoing outbreak in Central Africa. Because of drug resistance and toxicity risks with current antiviral treatments, there is still a need for additional antivirals to treat mpox and other orthopoxvirus diseases. We developed in vitro screening assays using recombinant strains of vaccinia virus and MPXV to measure the antiviral potency of compounds, finding that adefovir dipivoxil and tenofovir alafenamide had potent anti-orthopoxvirus activity and low toxicity. These data reinforce interest in repurposing nucleoside analogues as antivirals to treat poxvirus infections and provide a basis for high throughput screening and mechanistic and antiviral resistance studies.

Authors

Institutions

Publication Details

Journal
Journal of Medical Virology
Published
2025-10-25
DOI
https://doi.org/10.1002/jmv.70669
Primary Topic
Poxvirus research and outbreaks
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Monkeypox Virus Is Inhibited by Nucleoside Analogues Including the Acyclic Phosphonates Adefovir and Tenofovir In Vitro

Emerson Ailidh Boggs, Jasper Lee, Christina L. Hutson, Panayampalli S. Satheshkumar et al.
Journal of Medical Virology
Poxvirus research and outbreaks
article

Monkeypox Virus Is Inhibited by Nucleoside Analogues Including the Acyclic Phosphonates Adefovir and Tenofovir In Vitro

Emerson Ailidh Boggs, Jasper Lee, Christina L. Hutson, Panayampalli S. Satheshkumar, Haian Fu, Stefan G. Sarafianos, Huanchun Zhang, Philip R. Tedbury, Shuiyun Lan, Yuhong Du, Margaret Moriarty, Jesse Kilcullen
article en

Abstract

Mpox, caused by the orthopoxvirus monkeypox virus (MPXV), has garnered worldwide attention during a global outbreak in 2022 and in an ongoing outbreak in Central Africa. Because of drug resistance and toxicity risks with current antiviral treatments, there is still a need for additional antivirals to treat mpox and other orthopoxvirus diseases. We developed in vitro screening assays using recombinant strains of vaccinia virus and MPXV to measure the antiviral potency of compounds, finding that adefovir dipivoxil and tenofovir alafenamide had potent anti-orthopoxvirus activity and low toxicity. These data reinforce interest in repurposing nucleoside analogues as antivirals to treat poxvirus infections and provide a basis for high throughput screening and mechanistic and antiviral resistance studies.

Journal of Medical VirologyVol. 97(11)
Emory University (US), National Center for Emerging and Zoonotic Infectious Diseases (US), Children's Healthcare of Atlanta (US)
Emory University, University of Wisconsin-Madison, National Institutes of Health, Centers for Disease Control and Prevention
Openalex Percentile: Top 67%
Poxvirus research and outbreaks
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Monkeypox Virus Is Inhibited by Nucleoside Analogues Including the Acyclic Phosphonates Adefovir and Tenofovir In Vitro — Emerson Ailidh Boggs, Jasper Lee, et al. · Journal of Medical Virology (2025) | TGRS Research Map | TGRS